Evidence map›Paper›PMID 32354131›Full record

ArticleCancers2020

Early Moderate Intensity Aerobic Exercise Intervention Prevents Doxorubicin-Caused Cardiac Dysfunction Through Inhibition of Cardiac Fibrosis and Inflammation.

Hsin-Lun Yang, Pei-Ling Hsieh, Ching-Hsia Hung, Hui-Ching Cheng, Wan-Ching Chou, Pei-Ming Chu, Yun-Ching Chang, Kun-Ling Tsai

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06881940 (Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab), which is not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06881940 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab: A Randomized, Active Control Group, Open-Label Trial

TypeinterventionalSponsorInstituto Nacional de Cardiologia Ignacio ChavezRan2025 to 2029Enrolled284ConditionsCancer Therapy-Related Cardiac DysfunctionArmsRehabilitation Program, No Rehabilitation Program
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Hsin-Lun YangDepartment of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.
Pei-Ling HsiehDepartment of Anatomy, School of Medicine, China Medical University, Taichung 404, Taiwan.
Ching-Hsia HungDepartment of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.
Hui-Ching ChengDepartment of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.
Wan-Ching ChouDepartment of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.ORCID 0000-0003-1088-8587
Pei-Ming ChuDepartment of Anatomy, School of Medicine, China Medical University, Taichung 404, Taiwan.
Yun-Ching ChangDepartment of Nursing, Shu-Zen Junior College of Medicine and Management, Kaohsiung 821, Taiwan.
Kun-Ling TsaiDepartment of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.
National Cheng Kung University · TWChina Medical University · TWMin-Hwei College of Health Care Management · TW

Funding

Ministry of Science and Technology, Taiwan MOST-108-2320-B-006-053
6 · The paper itself

Abstract

Doxorubicin (DOX) is known as an effective drug in the fight against various cancers. However, one of the greatest impediments is DOX-induced cardiomyopathy, which may potentially lead to heart failure. Accumulating evidence has shed light on the pathological mechanism of DOX-induced cardiotoxicity, but treatments to mitigate the cardiac damage are still required. In an attempt to address this issue, we evaluated whether exercise provides cardioprotective effects on the DOX-induced cardiotoxicity. We showed that treadmill exercise (3 times/week; 1-week of exercise acclimatization and 4-weeks of endurance exercise) during the DOX treatment successfully prevented the cardiac dysfunction. The DOX-stimulated expression of IκBα, NF-κB, COX-2, and IL-8 were all downregulated by exercise as well as the fibrosis factors (TGF-β1, phosphorylated ERK, Sp1, and CTGF). Moreover, we showed that treadmill exercise diminished the expression of several cardiac remodeling-associated factors, such as FGF2, uPA, MMP2, and MMP9. These results were in line with the finding that exercise intervention reduced cardiac fibrosis and restored cardiac function, with higher values of ejection fraction and fractional shortening compared to the DOX-treated group. Two commonly used indicators of cardiac injury, lactate dehydrogenase, and creatine kinase-MB, were also decreased in the exercise group. Collectively, our results suggested that it may be beneficial to prescribe treadmill exercise as an adjunct therapy to limit cardiac damage caused by DOX.

Indexed as

cardiac fibrosiscardiac toxicitycardiomyocytesdoxorubicin

Identifiers

PMID32354131
PMCPMC7281105
OpenAlexW3023031566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.